The comparative effects of pioglitazone and rosiglitazone on lipoprotein sub-fractions in patients with type 2 diabetes and dyslipidemia

被引：0
|
作者：
Deeg, MA
Goldberg, RB
Buse, JB
Kendall, DM
Zagar, AJ
Pinaire, JA
Tan, MH
Khan, MA
Perez, AT
Jacober, SJ
机构：
来源：
DIABETES | 2005年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A234 / A235
页数：2
相关论文
共 50 条
  • [1] Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia
    Deeg, Mark A.
    Buse, John B.
    Goldberg, Ronald B.
    Kendall, David M.
    Zagar, Anthony J.
    Jacober, Scott J.
    Khan, Mehmood A.
    Perez, Alfonzo T.
    Tan, Meng H.
    [J]. DIABETES CARE, 2007, 30 (10) : 2458 - 2464
  • [2] A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
    Goldberg, RB
    Kendall, DM
    Deeg, MA
    Buse, JB
    Zagar, AJ
    Pinaire, JA
    Tan, MH
    Khan, MA
    Perez, AT
    Jacober, SJ
    [J]. CIRCULATION, 2005, 111 (13) : 1727 - 1728
  • [3] A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
    Goldberg, RB
    Kendall, DM
    Deeg, MA
    Buse, JB
    Zagar, AJ
    Pinaire, JA
    Tan, MH
    Khan, MA
    Perez, AT
    Jacober, SJ
    [J]. DIABETES CARE, 2005, 28 (07) : 1547 - 1554
  • [4] Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids
    Brackenridge, A. L.
    Jackson, N.
    Jefferson, W.
    Stolinski, M.
    Shojaee-Moradie, F.
    Hovorka, R.
    Umpleby, A. M.
    Russell-Jones, D.
    [J]. DIABETIC MEDICINE, 2009, 26 (05) : 532 - 539
  • [5] A comparison of effects of pioglitazone and rosiglitazone on serum lipoproteins and their subfractions in patients with type 2 diabetes and dyslipidemia
    Tan, MH
    Kendall, DM
    Deeg, MA
    Buse, JB
    Goldberg, R
    Zagar, AJ
    Khan, MA
    Perez, AT
    Jacober, SJ
    [J]. DIABETOLOGIA, 2005, 48 : A393 - A394
  • [6] A comparison of nontraditional atherogenic markers with pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
    Law, R
    Khan, M
    Perez, A
    Jacober, S
    Goldberg, R
    Kendall, D
    Deeg, M
    Tan, M
    Demissie, S
    [J]. DIABETOLOGIA, 2005, 48 : A286 - A286
  • [7] Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes
    Berneis, Kaspar
    Rizzo, Manfredi
    Stettler, Christoph
    Chappuis, Bernard
    Braun, Monica
    Diem, Peter
    Christ, Emanuel R.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (03) : 343 - 349
  • [8] A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia - Response to Bell and Brunzell
    Goldberg, RB
    Kendall, DM
    Deeg, MA
    Buse, JB
    Zagar, AJ
    Pinaire, JA
    Tan, MH
    Khan, MA
    Perez, AT
    Jacober, SJ
    [J]. DIABETES CARE, 2005, 28 (12) : 2985 - 2986
  • [9] Rosiglitazone or pioglitazone in type 2 diabetes?
    de Vries, Corinne S.
    Russell-Jones, David L.
    [J]. BRITISH MEDICAL JOURNAL, 2009, 339
  • [10] Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US
    Tunis, Sandra L.
    Minshall, Michael E.
    Charles, Meaghan St.
    Pandya, Bhavik J.
    Baran, Robert W.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (11) : 3085 - 3096
12345